Cancer clinical trials in the region Provence-Alpes-Côte d'Azur

439 currently recruiting clinical trials
Region Provence-Alpes-Côte d'Azur
Phase 1 / Phase 2 Breast cancer #NCT04939610 #2023-508995-12-01
Cancer du sein HER2+ Monotherapie
Required HER2 statuses
HER2 Positive
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
2 3 or more
Required previous treatments at advanced or metastatic stage
Targeted therapy Bispecific T-cell engager antibodies Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Novartis Pharmaceuticals
Phase 1 / Phase 2 Lung cancer #NCT04939610 #2023-508995-12-01
NSCLC Combinaison
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Novartis Pharmaceuticals
Phase 1 / Phase 2 Breast cancer #NCT04939610 #2023-508995-12-01
Cancer du sein triple négatif TNBC Monotherapie
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Negative
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
2 3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Novartis Pharmaceuticals
Phase 1 / Phase 2 Pancreas cancer #NCT04939610 #2023-508995-12-01
PDAC Monotherapie
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Novartis Pharmaceuticals
Phase 1 / Phase 2 Endometrial cancer #NCT06796907 #2024-517147-31-00
Module 1 Cancer endomètre
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
GlaxoSmithKline
Phase 1 / Phase 2 Ovarian / Fallopian tubes / Peritoneum cancer #NCT06796907 #2024-517147-31-00
Module 2 Cancer ovarien
Required histologic types
Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC) Serous low grade carcinoma (LGSOC) Endometrioid carcinoma Clear cell carcinoma Mucinous carcinoma Other epithelial ovarian cancer
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
GlaxoSmithKline
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT04939610 #2023-508995-12-01
Phase 1: Escalade de dose
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
Other mutation
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Novartis Pharmaceuticals
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer Brain tumors / Central nervous system tumors Skin cancer #NCT05706129 #2023-504254-35-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Squamous NSCLC
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Negative
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
8 recruiting sites
Debiopharm International SA
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer Brain tumors / Central nervous system tumors Skin cancer #NCT05768139 #2023-000442-41
Cohortes autres tumeurs solides
Required histologic types
Oral cavity Nasopharynx Oropharynx Hypopharynx Larynx Nasal cavities and sinuses
Required histologic sub types
Squamous cell carcinoma
Required HR statuses
HR Positive
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
PIK3CA
Required number of previous lines of therapy
1 2 3 or more
6 recruiting sites
Eli Lilly et compagnie
Phase 1 / Phase 2 Brain tumors / Central nervous system tumors #NCT07243470 #2023-510568-11-00
Cohorte autres gliomes
Required histologic types
Gliomas
Required histologic sub types
High-grade glioma
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments
Radiotherapy
Excluded genetic anomalies
IDH1/2
Excluded previous treatments
Bevacizumab
5 recruiting sites
Centre Léon Bérard